GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2019-2027

GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2019-2027

The global antithrombotic drugs market was valued at $26557.86 million in 2018 & is estimated to generate net revenue of approximately $47953.42 million by 2027, growing at a CAGR of 6.79%. Antiplatelet, anticoagulant, and thrombolytic agents are different types of antithrombotic agents that act through different clotting processes. The important drivers increasing growth in the global antithrombotic drugs market are increasing demand for NOACS and healthcare policies and programs by the government.

GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2019-2027

Request free sample

The global antithrombotic drugs market was valued at $26557.86 million in 2018 & is estimated to generate net revenue of approximately $47953.42 million by 2027, growing at a CAGR of 6.79%. Antiplatelet, anticoagulant, and thrombolytic agents are different types of antithrombotic agents that act through different clotting processes.

The following factors primarily drive the antithrombotic drugs market:

  • Growing demand for NOACS
  • The surge in hip and knee replacement surgeries
  • Healthcare policies and programs by government
  • Growing aging population

The important drivers increasing growth in the global antithrombotic drugs market are increasing demand for NOACS and healthcare policies and programs by the government. The increasing adoption rates of NOACs are driving market growth. NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. The governments of the various regions are taking initiatives to make the country healthy.

Antithrombotic drugs are used extensively for various health treatments. Anticoagulants, also referred to as blood-thinning agents are drugs that prevent clot formation and help in the free flow of blood in the body. The Anticoagulants by drugs type is segmented into Low Molecular Weight Heparin and Oral Anticoagulants (vitamin K antagonists). The anticoagulant by ROA has been divided into Oral and Injectables. Several agents alter coagulation through their ability to inhibit the aggregation of platelets. Aspirin’s antiplatelet action results in the decrease of the synthesis of endoperoxides and thromboxanes, which are substances that mediate platelet aggregation. Antithrombin agents act by reversibly binding to an active thrombin site or both the catalytic and anion- binding exosite of thrombin, inhibiting the effects of thrombin. Betrixaban (INN, code-named PRT-054021) is an anticoagulant drug that acts as a direct factor Xa inhibitor. Angiomax (bivalirudin), offered by The Medicines Co., is used for its anticoagulant properties on patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.

The high cost of NOACS and lack of resources in underdeveloped countries are the major factors hindering the antithrombotic drugs market. The cost of NOACs that are available in the market is higher than the conventional drugs such as Warfarin. The average price of generic warfarin for a months’ supply is more than the traditional drugs. Lack of financial resources, inadequate income, and ignorance about health conditions hinder the antithrombotic market growth in underdeveloped countries of Asia and Africa.

The global antithrombotic drugs market segments include antithrombotic drugs types.

Antithrombotic Drugs types are segmented into:

  • Market by antithrombotic drugs types
    • Anticoagulants
      • Anticoagulants by drugs type
        • Low Molecular Weight Heparin
        • Oral anticoagulants (vitamin k antagonists)
      • Anticoagulants by Rapid Onset Anticoagulant (ROA)
        • Oral
        • Injectables
      • Anticoagulants by drug class
        • Factor XA
        • DTIS
        • Heparin
        • Vitamin K antagonists
      • Anticoagulants by applications
        • PE
        • DVT
        • AF
        • Other anticoagulants applications
    • Antiplatelets
      • Oral antiplatelets
      • IV antiplatelets
    • Thrombin inhibitors
      • Direct factor XA inhibitors
      • Direct thrombin inhibitors
      • Thrombolytic agents

This report covers the present market conditions and the growth prospects of the global antithrombotic drugs market for 2019-2027 and considered the revenue generated through the sales of antithrombotic drugs. The base year considered is 2018 to calculate the market size.

Geographically, the global Antithrombotic drugs market has been segmented into four major regions, which include:

  • North America: The United States & Canada
  • Asia Pacific: China, India, Japan, South Korea, Australia, and Rest of APAC
  • Europe: The United Kingdom, France, Germany, Spain, Italy, and Rest of Europe
  • Rest of World: Latin America & Middle East and Africa

The antithrombotic drugs market in North America is expected to hold the largest share by 2027 and the possibilities of growing at a significant pace with the introduction of NOACs. North America constitutes a market share of approx. 38% during the forecast period. The warfarin showed high growth when compared with an oral anticoagulant. However, the revenue generated from the sales of warfarin is low due to the availability of generics, which are available at prices that are 15-20 times lower than that of NOACs. Anticoagulants are among the most frequently prescribed drugs in the United States. On the other hand, the Asia Pacific market is anticipated to the fastest-growing region for the antithrombotic drugs market. APAC is expected to increase at a fast pace when compared with Europe and the Americas owing to the low awareness. With the increasing awareness and improving healthcare infrastructure, the patient pool should increase in APAC.

The major market players in the global antithrombotic drugs market are:

  • ABBOT LABORATORIES
  • BAYER
  • ARMETHEON INC.
  • ELI LILLY AND COMPANY
  • BOEHRINGER INGELHEIM GMBH

Company Profiles covers the analysis of important players.

Abbott Laboratories (Abbott or ‘the company’) is a diversified healthcare company with a portfolio diagnostic products, medical devices, nutritionals and branded generic pharmaceuticals. The company markets its products in several countries, with major operations in the US, the Netherlands, Germany, Japan, Italy, France, Canada, the UK, and Spain. Eli Lilly and Company, is a pharmaceutical company based in Indiana, US, and was founded in 1876 by Eli Lilly. Eli Lilly and Company has its presence in the Americas, Asia Pacific, Africa, and Europe.

Key findings of the global antithrombotic drugs market:

  • Anticoagulants generate the highest revenue in the antithrombotic market
  • Oral antiplatelets are widely used
  • Direct factor XA inhibitors are anticipated to grow significantly during the forecast period
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • ANTICOAGULANTS GENERATES THE HIGHEST REVENUE IN ANTITHROMBTIC MARKET
      • ORAL ANTIPLATELETS ARE WIDELY USED
      • DIRECT FACTOR XA INHIBITORS ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVERS
      • GROWING DEMAND FOR NOACS
      • SURGE IN HIP AND KNEE REPLACEMENT SURGERIES
      • HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
      • GROWING AGING POPULATION
    • MARKET RESTRAINTS
      • HIGH COST OF NOACS
      • LACK OF RESOURCES IN UNDERDEVELOPED COUNTRIES
    • MARKET OPPORTUNITIES
      • GROWING PREVALENCE OF COAGULATION DISORDERS
      • GROWING HEALTHCARE INDUSTRIES
    • MARKET CHALLENGES
      • LACK OF NOACS ANTIDOTES IN THE MARKET
      • PATENT EXPIRATION
  1. MARKET BY ANTITHROMBOTIC DRUGS TYPE
    • ANTICOAGULANTS
      • ANTICOAGULANTS BY DRUGS TYPE
        • LOW MOLECULAR WEIGHT HEPARIN
        • ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
      • ANTICOAGULANTS BY RAPID ONSET ANTICOAGULANT (ROA)
        • ORAL
        • INJECTABLES
      • ANTICOAGULANTS BY DRUG CLASS
        • FACTOR XA
        • DTIS
        • HEPARIN
        • VITAMIN K ANTAGONISTS
      • ANTICOAGULANTS BY APPLICATIONS
        • PE
        • DVT
        • AF
        • OTHER ANTICOAGULANTS APPLICATIONS
    • ANTIPLATELETS
      • ORAL ANTIPLATELETS
      • IV ANTIPLATELETS
    • THROMBIN INHIBITORS
      • DIRECT FACTOR XA INHIBITORS
      • DIRECT THROMBIN INHIBITORS
      • THROMBOLYTIC AGENTS
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCES MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF RIVALRY
    • PATENT ANALYSIS
    • MARKET TRENDS
      • STRATEGIC ALLIANCE
      • INCREASING FOCUS TOWARD EMERGING ECONOMIES
    • KEY DRUGS IN ANTITHROMBIC DRUGS MARKET
    • KEY BUYING CRITERIA
    • OPPORTUNITY MATRIX
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • MIDDLE EAST AND AFRICA (MEA)
      • LATIN AMERICA
  1. COMPANY PROFILES
    • ABBOT LABORATORIES
    • ESPERO BIOPHARMA
    • BAXTER INTERNATIONAL, INC.
    • BAYER AG
    • BOEHRINGER INGELHEIM GMBH
    • BRISTOL-MYERS SQUIBB CO.
    • CSL BEHRING
    • DAIICHI SANKYO CO. LTD.
    • ELI LILLY AND COMPANY
    • HOFFMANN-LA ROCHE LTD.
    • GLAXOSMITHKLINE PLC
    • JOHNSON & JOHNSON
    • MERCK & CO., INC.
    • NOVARTIS AG
    • PFIZER INC.
    • SANOFI SA

 

LIST OF TABLES

TABLE 1        GLOBAL ANTITHROMBOTIC MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 2        INDIAN GOVERNMENT INITIATIVES IN HEALTHCARE SECTOR

TABLE 3        GLOBAL ANTITHROMBOTIC DRUGS MARKET, BY TYPE, 2019-2027 ($ MILLION)

TABLE 4        GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY REGION, 2019-2027 ($ MILLION)

TABLE 5        GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY DRUGS TYPE 2019-2027 ($ MILLION)

TABLE 6        GLOBAL ANTICOAGULANTS MARKET IN LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2019-2027 ($ MILLION)

TABLE 7        LOVENOX DRUG BRAND

TABLE 8        GLOBAL ANTICOAGULANTS MARKET IN LOW ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS), BY REGION, 2019-2027 ($ MILLION)

TABLE 9        GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY ROA, 2019-2027 ($ MILLION)

TABLE 10      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY DRUG CLASS, 2019-2027 ($ MILLION)

TABLE 11      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY APPLICATIONS, 2019-2027 ($ MILLION)

TABLE 12      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS, BY REGION, 2019-2027 ($ MILLION)

TABLE 13      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS, BY TYPES, 2019-2027 ($ MILLION)

TABLE 14      GLOBAL ANTIPLATELETS MARKET IN ORAL ANTIPLATELETS, BY REGION, 2019-2027 ($ MILLION)

TABLE 15      GLOBAL ANTIPLATELETS MARKET IN IV ANTIPLATELETS, BY REGION, 2019-2027 ($ MILLION)

TABLE 16      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS, BY REGION, 2019-2027 ($ MILLION)

TABLE 17      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS, BY TYPES, 2019-2027 ($ MILLION)

TABLE 18      NUMBER OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, BY VARIOUS COMPANIES, 2011-2016

TABLE 19      NUMBERS OF PATENTS ON ANTICOAGULANTS, BY VARIOUS COMPANIES, 2011-2016

TABLE 20      NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 21      EUROPE ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

TABLE 22      ASIA PACIFIC ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

TABLE 23      REST OF WORLD ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

LIST OF FIGURES

FIGURE 1      GLOBAL ANTITHROMBOTIC MARKET, BY REGION, 2019-2027 ($ MILLION)

FIGURE 2      INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)

FIGURE 3      GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, 2019-2027 ($ MILLION)

FIGURE 4      BLOOD COAGULATION PROCESS

FIGURE 5      GLOBAL ANTICOAGULANTS MARKET IN ORAL, 2019-2027 ($ MILLION)

FIGURE 6      GLOBAL ANTICOAGULANTS MARKET IN INJECTABLES, 2019-2027 ($ MILLION)

FIGURE 7      GLOBAL ANTICOAGULANTS MARKET IN FACTOR XA, 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL ANTICOAGULANTS MARKET IN DTIS, 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL ANTICOAGULANTS MARKET IN HEPARIN, 2019-2027 ($ MILLION)

FIGURE 10   GLOBAL ANTICOAGULANTS MARKET IN VITAMIN K ANTAGONISTS, 2019-2027 ($ MILLION)

FIGURE 11   GLOBAL ANTICOAGULANTS MARKET IN PE, 2019-2027 ($ MILLION)

FIGURE 12   GLOBAL ANTICOAGULANTS MARKET IN DVT, 2019-2027 ($ MILLION)

FIGURE 13   GLOBAL ANTICOAGULANTS MARKET IN AF, 2019-2027 ($ MILLION)

FIGURE 14   GLOBAL ANTICOAGULANTS MARKET IN OTHER ANTICOAGULANTS APPLICATIONS, 2019-2027 ($ MILLION)

FIGURE 15   GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS, 2019-2027 ($ MILLION)

FIGURE 16   GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS, 2019-2027 ($ MILLION)

FIGURE 17   GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT FACTOR XA INHIBITORS, 2019-2027 ($ MILLION)

FIGURE 18   GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT THROMBIN INHIBITORS, 2019-2027 ($ MILLION)

FIGURE 19   GLOBAL THROMBIN INHIBITORS MARKET IN THROMBOLYTIC AGENTS, 2019-2027 ($ MILLION)

FIGURE 20   PORTER’S FIVE FORCE MODEL

FIGURE 21   GLOBAL ANTITHROMBOTIC DRUGS MARKET, BY REGION, 2019-2027 ($ MILLION)

FIGURE 22   THE UNITED STATES ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 23   CANADA ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 24   THE UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 25   FRANCE ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 26   GERMANY ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 27   SPAIN ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 28   ITALY ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 29   REST OF EUROPE ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 30   INDIA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)

FIGURE 31   CHINA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)

FIGURE 32   JAPAN ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)

FIGURE 33   SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)

FIGURE 34   AUSTRALIA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)

FIGURE 35   REST OF APAC ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)

FIGURE 36   MIDDLE EAST AND AFRICA ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE 37   LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

  1. MARKET BY ANTITHROMBOTIC DRUGS TYPE
    • ANTICOAGULANTS
      • ANTICOAGULANTS BY DRUGS TYPE
        • LOW MOLECULAR WEIGHT HEPARIN
        • ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
      • ANTICOAGULANTS BY RAPID ONSET ANTICOAGULANT (ROA)
        • ORAL
        • INJECTABLES
      • ANTICOAGULANTS BY DRUG CLASS
        • FACTOR XA
        • DTIS
        • HEPARIN
        • VITAMIN K ANTAGONISTS
      • ANTICOAGULANTS BY APPLICATIONS
        • PE
        • DVT
        • AF
        • OTHER ANTICOAGULANTS APPLICATIONS
    • ANTIPLATELETS
      • ORAL ANTIPLATELETS
      • IV ANTIPLATELETS
    • THROMBIN INHIBITORS
      • DIRECT FACTOR XA INHIBITORS
      • DIRECT THROMBIN INHIBITORS
      • THROMBOLYTIC AGENTS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • MIDDLE EAST AND AFRICA (MEA)
      • LATIN AMERICA

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now